Blog
RSS FeedPosted by Michael Wonder on 12 May 2022
ATAGI update following weekly COVID-19 meeting (11 May 2022)
12 May 2022 - On Wednesday 11 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 12 May 2022
COVID-19 vaccine weekly safety report (12 May 2022)
12 May 2022 - To 8 May 2022, the TGA has received 554 reports which have been assessed as likely to ...
Posted by Michael Wonder on 11 May 2022
ATAGI update following weekly COVID-19 meeting (4 May 2022)
9 May 2022 - On Wednesday 4 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 05 May 2022
COVID-19 vaccine weekly safety report (5 May 2022)
5 May 2022 - To 1 May 2022, the TGA has received 546 reports which have been assessed as likely to ...
Posted by Michael Wonder on 28 Apr 2022
COVID-19 vaccine weekly safety report (28 April 2022)
28 April 2022 - To 24 April 2022, the TGA has received 544 reports which have been assessed as likely to ...
Posted by Michael Wonder on 28 Apr 2022
TGA grants provisional determination for the Moderna bivalent COVID-19 vaccine "Spikevax Bivalent Zero/Omicron"
28 April 2022 - On 27 April 2022, the TGA granted a provisional determination to Moderna in relation to its ...
Posted by Michael Wonder on 21 Apr 2022
COVID-19 vaccine weekly safety report (24 April 2022)
24 April 2022 - To 17 April 2022, the TGA has received 534 reports which have been assessed as likely to ...
Posted by Michael Wonder on 19 Apr 2022
Prescription medicines: applications under evaluation (April 2022)
19 April 2022 - The TGA has updated its list of applications for new medicines or new uses for existing medicines ...
Posted by Michael Wonder on 14 Apr 2022
COVID-19 vaccine weekly safety report (14 April 2022)
14 April 2022 - To 10 April 2022, the TGA has received 528 reports which have been assessed as likely to ...
Posted by Michael Wonder on 09 Apr 2022
ATAGI statement on use of booster doses in adolescents aged 12-15 years
8 April 2022 - A statement from the ATAGI on booster doses in adolescents aged 12-15 years. ...
Posted by Michael Wonder on 08 Apr 2022
TGA provisionally approves Pfizer’s COVID-19 vaccine (Comirnaty), for use as a booster for individual aged 12–15 years old
8 April 2022 - The TGA has provisionally approved the Pfizer Australia Pty Ltd COVID-19 vaccine, Comirnaty, for use as a ...
Posted by Michael Wonder on 07 Apr 2022
COVID-19 vaccine weekly safety report (7 April 2022)
7 April 2022 - To 3 April 2022, the TGA has received 511 reports which have been assessed as likely to ...
Posted by Michael Wonder on 31 Mar 2022
COVID-19 vaccine weekly safety report (31 March 2022)
31 March 2022 - To 27 March 2022, the TGA has received 509 reports which have been assessed as likely to ...
Posted by Michael Wonder on 28 Mar 2022
ATAGI update following weekly COVID-19 meeting (23 March 2022)
28 March 2022 - ATAGI have provided recommendations on a winter booster dose of COVID-19 vaccine to increase vaccine protection ...
Posted by Michael Wonder on 28 Mar 2022
2022 seasonal influenza vaccines
25 March 2022 - The Australian Influenza Vaccine Committee has reviewed data related to epidemiology, antigenic and genetic characteristics of recent ...